Header Image

Latest News

Latest News

Filter Releases
 
Latest News
Date Title and Summary View
Jul 22, 2013
BioCryst initiating a Phase 2a trial in hereditary angioedema patients in 2013 Management to discuss results during conference call at 8:30 a.m. Eastern Time RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (...
Jul 11, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the Biomedical Advanced Research and Development Authority (BARDA/HHS) has released funding under the current $234.8 million contract to enable completion of a New Drug Application (NDA) fili...
Jul 1, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company's clinical programs at the 8th Annual JMP Securities Healthcare Conference i...
May 9, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that executives from BioCryst are scheduled to present and provide a corporate summary and update regarding the Company's clinical programs at the following investor conferences: ...
May 7, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the first quarter ended March 31, 2013. "We are pleased that our recent interactions with the FDA have defined a pathway to file a peramivir NDA for ...
Apr 23, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its first quarter 2013 financial results will be released on Tuesday, May 7, 2013. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss the financial results...
Apr 16, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it has completed its Type C meeting regarding intravenous (i.v.) peramivir with the U.S. Food & Drug Administration (FDA) and has received final meeting minutes. The minutes of the meeting we...
Apr 1, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that it received a preliminary comment letter from the U.S. Food & Drug Administration (FDA) that outlines a pathway by which BioCryst could file a New Drug Application (NDA) seeking regulatory ap...
Mar 25, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the initiation of a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of orally-administered BCX4161 in healthy volunteers. Discovered by BioCryst, BCX4161 is a ...
Feb 19, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced financial results for the fourth quarter and full year ended December 31, 2012. "Our team is focused on achieving near-term milestones to rebuild shareholder value. Our primary goa...
Feb 5, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that its fourth quarter and full year 2012 financial results will be released on Tuesday, February 19, 2013. BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss ...
Jan 2, 2013
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that Jon Stonehouse, President and Chief Executive Officer of BioCryst is scheduled to present and provide a corporate summary and update regarding the Company at the 31st annual J.P. Morgan ...
Dec 7, 2012
2013 cash utilization projected to drop 38-45% versus 2012 RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced today that in response to recent events and an assessment of its assets, the Company is restructuring and implementing a ...
Nov 30, 2012
RESEARCH TRIANGLE PARK, N.C. & SAN FRANCISCO--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) and privately held Presidio Pharmaceuticals, Inc. today announced the mutual termination of the Merger Agreement and the related Investor Financing Agreement entered into on October 17, 2012. Although the ...
Nov 12, 2012
Results to be presented at the 2nd Antiviral Congress today RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced proof-of-principle data demonstrating that BCX4430 is efficacious and well tolerated in a preclinical dis...
Page: First Previous
...
...
Next Last